{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:21:28Z","timestamp":1785842488658,"version":"3.56.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2211,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1093\/annonc\/mdt311","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T18:26:35Z","timestamp":1381947995000},"page":"viii47-viii53","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S8","title":["Alternatives to risk-reducing surgery for ovarian cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"A.","family":"Gadducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sergiampietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt311_bb0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","article-title":"Epidemiology of ovarian cancer","volume":"472","author":"Permuth-Wey","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1093\/annonc\/mdt311_bb0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary cancer predisposition syndromes","volume":"23","author":"Garber","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/uog.65","article-title":"Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study","volume":"21","author":"Tailor","year":"2003","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1093\/annonc\/mdt311_bb0025","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1-mutation carriers. breast cancer linkage consortium","volume":"56","author":"Easton","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mdt311_bb0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1093\/annonc\/mdt311_bb0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mdt311_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/00016340500324621","article-title":"Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention","volume":"85","author":"S\u00f8gaard","year":"2006","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1093\/annonc\/mdt311_bb0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2005.03.6772","article-title":"Characterization of BRCA1 and BRCA2 mutations in a large United States sample","volume":"24","author":"Chen","year":"2006","journal-title":"Clin Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0050","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","article-title":"Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up","volume":"90","author":"Olivier","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0055","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","article-title":"Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers","volume":"91","author":"Rebbeck","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt311_bb0060","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt311_bb0065","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt311_bb0070","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/95.14.1072","article-title":"Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study","volume":"95","author":"Rutter","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt311_bb0075","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","article-title":"Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers","volume":"23","author":"Kramer","year":"2005","journal-title":"J ClinOncol"},{"key":"10.1093\/annonc\/mdt311_bb0080","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J ClinOncol"},{"key":"10.1093\/annonc\/mdt311_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"7","author":"Domchek","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt311_bb0095","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1055-9965.EPI-06-0829","article-title":"Age at menarche and menopause and breast cancer risk in the International BRCA1\/2 Carrier Cohort Study","volume":"16","author":"Chang-Claude","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdt311_bb0100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multi-center, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt311_bb0110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/IGC.0b013e318257b936","article-title":"Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population","volume":"22","author":"Bacha","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0120","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2009.89","article-title":"Candidate serous cancer precursors in fallopian tube epithelium of BRCA1\/2 mutation carriers","volume":"22","author":"Shaw","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","article-title":"A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations","volume":"109","author":"Folkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0135","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0140","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1093\/annonc\/mdt311_bb0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1525-1438.2007.01039.x","article-title":"Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance","volume":"18","author":"Salani","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0160","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0165","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0170","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3109\/09513590.2011.649595","article-title":"New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications","volume":"28","author":"Gadducci","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1093\/annonc\/mdt311_bb0175","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt311_bb0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl. 10","key":"10.1093\/annonc\/mdt311_bb0185","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","article-title":"Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers","volume":"76","author":"Skates","year":"1995","journal-title":"Cancer"},{"issue":"Suppl. 10","key":"10.1093\/annonc\/mdt311_bb0190","doi-asserted-by":"crossref","first-page":"206s","DOI":"10.1200\/JCO.2003.02.955","article-title":"Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women","volume":"21","author":"Skates","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0195","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/IGC.0b013e318251cb47","article-title":"The UKCTOCS experience\u2013reasons for hope?","volume":"22","author":"Menon","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0200","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/ijc.27909","article-title":"Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.","volume":"132","author":"Pinsky","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/ijgc-00009577-200201000-00014","article-title":"Use of CA-125 and ultrasound in high-risk women","volume":"12","author":"Laframboise","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0210","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.20.6.1570","article-title":"Cancer incidence in a population of Jewish women at risk of ovarian cancer","volume":"20","author":"Liede","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0215","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.20.5.1260","article-title":"Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers","volume":"20","author":"Scheuer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0220","doi-asserted-by":"crossref","first-page":"411","DOI":"10.7205\/MILMED.169.6.411","article-title":"Outcome of five years of accelerated surveillance in patients at high risk for inherited breast\/ovarian cancer: report of a phase II trial","volume":"169","author":"Fries","year":"2004","journal-title":"Mil Med"},{"key":"10.1093\/annonc\/mdt311_bb0225","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cncr.21148","article-title":"Ovariancarcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up","volume":"104","author":"Kauff","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0230","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ygyno.2005.01.024","article-title":"Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer","volume":"97","author":"Meeuwissen","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mdt311_bb0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ijgc-00009577-200602001-00009","article-title":"Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study","volume":"16","author":"Gaarenstroom","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0240","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ejca.2004.10.029","article-title":"Early detection of breast and ovarian cancer in families with BRCA mutations","volume":"41","author":"Vasen","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0245","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0250","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J ClinOncol"},{"key":"10.1093\/annonc\/mdt311_bb0255","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.bjc.6603015","article-title":"Surveillance of women at high risk for hereditary ovarian cancer is inefficient","volume":"94","author":"Oei","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0260","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.287.13.1671","article-title":"Osteopontin as a potential diagnostic biomarker for ovarian cancer","volume":"287","author":"Kim","year":"2002","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt311_bb0265","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","article-title":"Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt311_bb0270","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"10.1093\/annonc\/mdt311_bb0275","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"Mor","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdt311_bb0280","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/1078-0432.CCR-07-1569","article-title":"Diagnostic markers for early detection of ovarian cancer","volume":"14","author":"Visintin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt311_bb0285","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvicmass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0290","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0295","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2011.06.002","article-title":"Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer","volume":"122","author":"Clarke","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0300","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2011.07.018","article-title":"A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer","volume":"123","author":"H\u00f8gdall","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cncr.26241","article-title":"Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial","volume":"118","author":"Moore","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0310","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-04-1870","article-title":"Plasma prolactin concentrations and risk of postmenopausal breast cancer","volume":"64","author":"Tworoger","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt311_bb0315","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-03-0093","article-title":"Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size","volume":"10","author":"Singer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt311_bb0320","doi-asserted-by":"crossref","first-page":"204","DOI":"10.14310\/horm.2002.1169","article-title":"Leptin, nutrition and reproduction: new insights","volume":"1","author":"Popovic","year":"2002","journal-title":"Hormones"},{"key":"10.1093\/annonc\/mdt311_bb0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0070-2153(05)68003-9","article-title":"Corpus luteum development: lessons from genetic models in mice","volume":"68","author":"Bachelot","year":"2005","journal-title":"Curr Top DevBiol"},{"key":"10.1093\/annonc\/mdt311_bb0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7827-1-12","article-title":"Effects of deletion of the prolactin receptor on ovarian gene expression","volume":"1","author":"Grosdemouge","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1093\/annonc\/mdt311_bb0335","first-page":"S26","article-title":"Insulin-like growth factor family in Graafian follicle development and function","volume":"8","author":"Giudice","year":"2001","journal-title":"J Soc Gynecol Investig"},{"key":"10.1093\/annonc\/mdt311_bb0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.cej.0000179274.24200.9d","article-title":"Oral contraceptives and ovarian cancer: an update, 1998\u20132004","volume":"15","author":"La Vecchia","year":"2006","journal-title":"Eur J Cancer Prev"},{"key":"10.1093\/annonc\/mdt311_bb0345","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","article-title":"Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study","volume":"335","author":"Hannaford","year":"2007","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdt311_bb0350","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Collaborative Group on Epidemiological Studies of Ovarian Cancer, Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt311_bb0355","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bpobgyn.2008.11.003","article-title":"Contraception and gynaecological care","volume":"23","author":"Cameron","year":"2009","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1093\/annonc\/mdt311_bb0360","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt311_bb0365","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","article-title":"Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations","volume":"491","author":"Whittemore","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0370","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/aje\/kwh284","article-title":"Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations","volume":"160","author":"McGuire","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1093\/annonc\/mdt311_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0380","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carrier Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdt311_bb0385","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdt311_bb0390","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1040-8428(01)00144-5","article-title":"Retinoids and their receptors in cancer development and chemoprevention","volume":"41","author":"Sun","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt311_bb0395","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0277-5379(91)90471-O","article-title":"Distribution of fenretinide in the mammary gland of breast cancer patients","volume":"27","author":"Mehta","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt311_bb0400","doi-asserted-by":"crossref","first-page":"172897","DOI":"10.1155\/2012\/172897","article-title":"Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?","volume":"2012","author":"Cazzaniga","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1093\/annonc\/mdt311_bb0405","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/jnci\/91.21.1847","article-title":"Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer","volume":"91","author":"Veronesi","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt311_bb0410","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt311_bb0415","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/carcin\/18.5.943","article-title":"Role of antioxidants and intracellular free radicals in retinamide-induced cell death","volume":"18","author":"Delia","year":"1997","journal-title":"Carcinogenesis"},{"key":"10.1093\/annonc\/mdt311_bb0420","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/92.23.1897","article-title":"Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism","volume":"92","author":"Maurer","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt311_bb0425","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/carcin\/bgp067","article-title":"PLAB Induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation","volume":"30","author":"Appierto","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1093\/annonc\/mdt311_bb0430","doi-asserted-by":"crossref","first-page":"e39968","DOI":"10.1371\/journal.pone.0039968","article-title":"AF1q: a novel mediator of basal and 4-HPR-induced apoptosis in ovarian cancer cells","volume":"7","author":"Tiberio","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdt311_bb0435","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a gynecologic oncology","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_8\/viii47\/6675870\/mdt311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T08:31:40Z","timestamp":1582187500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419315947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":86,"alternative-id":["S0923753419315947"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt311","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}